Cognition Therapeutics reports preliminary FY2023 net loss of $25.6M; cash at $29.9M

COGNITION THERAPEUTICS INC

Preliminary net loss for FY2023 expected to be approximately $25.6 million.
Cash and cash equivalents as of Dec 31, 2023: $29.9 million.
Results are unaudited and subject to revision upon completion of audit.
No revenue reported; company is a clinical-stage biotech.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income approximately $25.6 million.

Period: the year ended December 31, 2023
Net income: approximately $25.6 million
Result: preliminary results

Exact text from the filing

Preliminary unaudited consolidated operating results for the year ended December 31, 2023 and certain preliminary financial condition information as of December 31, 2023 are as follows: · Net loss for the year ended December 31, 2023 is expected to be approximately $25.6 million.

View on SEC.gov

Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-032979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.